Klinikum Erfurt implements 3D printing for personalized medication dosage in clinical study. Helios-Klinikum Erfurt has launched a clinical study involving over 1,000 patients across four German hospitals to validate the use of 3D-printed medication. Led by Dr. Alexander Krauel and Dr. Jana Giesel-Gerstmeier, the initiative utilizes a specialized extrusion-based 3D printer that replaces standard cartridges with syringes containing active pharmaceutical ingredients. The system allows for the precise adjustment of dosage, shape, and consistency, including the production of soft, palatable formulations tailored for pediatric and geriatric patients who struggle with conventional tablet sizes.

This development highlights the transition of additive manufacturing from industrial prototyping into decentralized, point-of-care pharmaceutical production. By moving away from mass-produced tablets that require splitting or crushing, the hospital addresses significant challenges in medication adherence and dosage accuracy for vulnerable populations. While traditional pharmaceutical manufacturing relies on high-volume compression, this AM-based approach enables on-demand customization within a hospital pharmacy setting. The integration of this technology into the European Pharmacopoeia framework remains a primary hurdle for broader clinical adoption.

For healthcare providers, the practical utility of this technology lies in its ability to improve patient compliance through taste masking and flexible dosing. The success of this implementation depends on the team's ability to satisfy regulatory requirements for quality control and batch consistency in a clinical environment. Future adoption will rely on demonstrating that these printed formulations provide equivalent bioavailability to standard oral dosage forms while reducing the labor-intensive preparation currently required by nursing staff.